By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
MediScope OnlineMediScope OnlineMediScope Online
  • Home
  • Global Innovation
  • MedTech & BioPharma
  • Insights
  • Innovación Global
  • Médicas y Biofarmacéuticas
  • Perspectivas
Notification Show More
Font ResizerAa
MediScope OnlineMediScope Online
Font ResizerAa
  • Home
  • Global Innovation
  • MedTech & BioPharma
  • Insights
  • Innovación Global
  • Médicas y Biofarmacéuticas
  • Perspectivas
  • Home
  • Global Innovation
  • MedTech & BioPharma
  • Insights
  • Innovación Global
  • Médicas y Biofarmacéuticas
  • Perspectivas
Follow US
MediScope Online > Blog > MedTech & BioPharma > Fully Automated Artificial Pancreas for Type 1 Diabetes
MedTech & BioPharma

Fully Automated Artificial Pancreas for Type 1 Diabetes

Emma Collins, Emma Collins
Last updated: 2025-08-25 17:48
By Emma Collins, Emma Collins
Share
2 Min Read
SHARE

The University of Virginia Health System (UVA Health) has released a new study indicating that if artificial pancreas systems can achieve true full automation, they will significantly improve blood glucose control in patients with type 1 diabetes and reduce the risk of complications. The findings, published in Diabetes Care, have drawn wide attention in the diabetes research community.

How the Artificial Pancreas Works
An “artificial pancreas” is a closed-loop system that integrates a continuous glucose monitor (CGM), an insulin pump, and intelligent algorithms. Its core principle is to mimic the function of a healthy pancreas: continuously monitoring glucose levels and automatically adjusting insulin delivery to maintain glucose within the target range.

In a clinical trial involving over one hundred patients, UVA Health researchers found that reducing the need for patient manual input (such as estimating carbohydrate intake before meals) and moving toward full automation significantly increased patients’ time in range (TIR). Moreover, nighttime hypoglycemia events were notably reduced.

Study lead Dr. Boris Kovatchev, professor of diabetes technology, explained: “For many patients, managing diabetes feels like a 24-hour job. A fully automated artificial pancreas could ease this burden and greatly improve quality of life.”

Currently available artificial pancreas systems still require partial manual input, limiting accessibility and convenience. Researchers believe that achieving a fully closed-loop system could particularly benefit adolescents and elderly patients by reducing dependency and operational complexity. Experts suggest that this technology may become the future gold standard for type 1 diabetes management, with potential applications for type 2 diabetes as well.

The UVA team plans to collaborate with medical device companies to accelerate product development and seek further FDA approval for clinical trials. If regulatory processes advance smoothly, such systems could enter clinical use within the next few years.

TAGGED:artificial pancreasartificial pancreas deviceautomated glucose controlclosed loop insulin systemdiabetes management technologydiabetes technologydigital health innovationfully automated insulin deliveryfuture of endocrinologytype 1 diabetes treatment
Share This Article
Facebook Copy Link Print
尚無留言 尚無留言

發佈留言 取消回覆

很抱歉,必須登入網站才能發佈留言。

Fast Four Quiz: Precision Medicine in Cancer

How much do you know about precision medicine in cancer? Test your knowledge with this quick quiz.
Get Started
The EU MDR Is Fully in Force: How Can SMEs Survive and Break Through?

With the EU …

A Global View of Healthcare Systems: From the NHS to Medicare, Exploring Different Models

This report …

EU MDR in Force: Operating Room Devices Enter a New Era of Compliance

SURGICAL ROO…

Your one-stop resource for medical news and education.

Your one-stop resource for medical news and education.
Sign Up for Free

You Might Also Like

Global InnovationMedTech & BioPharma

Medicine Meets AI: How Big Data Drives Better Treatments

By yogi
MedTech & BioPharma

Breakthrough: Lab-Grown Kidneys Offer New Hope

By Mitchell, Sarah Mitchell
MedTech & BioPharma

HHS Axes 22 mRNA Contracts, Redirects $500M in Research Funds

By Clarke, Emily
MedTech & BioPharma

Asian Manufacturing Turns the Tide: Central America’s Medical Market Faces a New Reality

By Clarke, Emily
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Editorial Policy
  • Accessibility Statement
  • Contact US
  • Feedback
  • Advertisement
More Info
  • Newsletter
  • MedTech & BioPharma
  • Insights
  • Global Innovation
  • 最新消息

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

Join Community
Made by ThemeRuby using the Foxiz theme. Powered by WordPress
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?